Altria Group Inc. released its latest quarterly earnings, driving interest among investors and analysts alike. The company's revenue met expectations, resulting in a volatile market reaction. Significant drivers contributing to this result include ongoing litigation. The future for Altria present

The FDA has issued a warning about the risks of smuggled tirzepatide as the peptide therapeutics market grows rapidly. The market is expected to jump from $38 billion in 2023 to $106 billion by 2033, with an impressive 10.8% compound annual growth rate. Legitimate peptide medications have copyright